Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:BDSX

Biodesix Q3 2026 Earnings Date & Estimates

Biodesix logo
$26.02 +0.39 (+1.52%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$26.00 -0.02 (-0.07%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biodesix in Q3 2026

Biodesix is expected to post earnings of -$0.75 per share on revenue of $27.55 million. In the same quarter a year earlier Biodesix reported -$1.16 per share on revenue of $21.77 million. Biodesix last reported on August 5, 2026, posting -$0.71 per share and beating the -$0.9018 consensus estimate. Biodesix has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.75
Expected Revenue
$27.55 million
Prior-Year EPS
-$1.16
Prior-Year Revenue
$21.77 million
Expected Revenue Growth
+26.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.71 (Beat by +$0.1918)
Last Quarter Revenue
$26.86 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Biodesix Q3 2026 Earnings FAQ

Biodesix (NASDAQ:BDSX) is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes.

Biodesix's Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biodesix to post earnings of -$0.75 per share for Q3 2026.

The consensus revenue estimate for Biodesix is $27.55 million for Q3 2026.

Biodesix Earnings Headlines

Biodesix consensus price target raised by 12.20% to $37.54
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/biodesix-consensus-price-target-raised-by-12-20-to-37-54/ar-AA2dqnEo
Biodesix, Inc. (NASDAQ:BDSX) Stock Rated "Moderate Buy" by Sell-Side Analysts
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077727
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
 |  Investors Alley (Ad)
Biodesix, Inc. (BDSX) Stock Price, News, Quote & History - Yahoo Finance
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/BDSX/latest-news/
Biodesix Inc.
September 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/bdsx/financials
Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo Fisher
September 27, 2026  |  rttnews.comhttps://www.rttnews.com/3694086/biodesix-reveals-two-developing-mrd-solution-collaborations-with-bio-rad-and-thermo-fisher.aspx
See More Biodesix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biodesix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biodesix and other key companies, straight to your email.

About Biodesix

Biodesix (NASDAQ:BDSX) is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of cancer, with an emphasis on lung disease. The company combines blood-based testing, data science and artificial intelligence to help physicians assess cancer risk, guide treatment decisions and monitor patients.

Biodesix’s portfolio includes diagnostic tests for lung nodules and lung cancer, including the Nodify Lung Nodule Risk Assessment suite and blood-based assays such as GeneStrat and VeriStrat. These products are designed to support the evaluation of suspicious lung nodules, identify molecular characteristics of tumors and help inform therapy selection and patient management.

The company serves healthcare providers, health systems, laboratories and biopharmaceutical companies, primarily in the United States. Its offerings are used in clinical care as well as in pharmaceutical development and research. Biodesix was founded in 2005 and became a publicly traded company on the Nasdaq in 2021.

View Biodesix Profile
Earnings Tools